Fig. 2
From: High HSPA8 expression predicts adverse outcomes of acute myeloid leukemia
HSPA8 acts as an adverse prognostic factor for CN-AML patients. a OS analysis of HSPA8 in CN- AML group patients (GSE12417- GPL96 HSPA8high group = 21, HSPA8low group = 42); b OS analysis of HSPA8 in CN-AML group patients (GSE12417- GPL570 HSPA8high group = 41, HSPA8low group = 38); c OS analysis of HSPA8 in CN- AML group patients (GSE12417- GPL97 HSPA8high group = 52, HSPA8low group = 111); d OS analysis of HSPA8 in CN- AML group patients (TCGA dataset, HSPA8high group = 38, HSPA8low group = 39); e OS analysis of HSPA8 in CN- AML (non-FLT3 mutant) patients (TCGA dataset, HSPA8high group = 16, HSPA8low group = 34)